UQ and Vaxxas win global prize to accelerate patch-based mRNA vaccine for COVID-19

The University of Queensland’s BASE facility – within the Australian Institute for Bioengineering and Nanotechnology (AIBN) – and Brisbane-based biotechnology company Vaxxas have been announced as stage winners of a prestigious global prize to accelerate a patch-based mRNA vaccine for COVID-19.

GSK’s RSV vaccine Arexvy shows long-term protection in Phase 3 trial

Sign up for free to read a limited number of articles each month. Pick what newsletters get delivered to your inbox each week. Biopharma ENDPOINTS

October 9, 2024

Agreement on the Acquisition of Almost All Assets – Biotech Investments

Epigenomics AG / Key word(s): Strategic Company Decision/Contract Epigenomics AG: Agreement on the Acquisition of Almost All Assets 24-Jul-2023 / 18:29 CET/CEST Disclosure of an

July 25, 2023

Gilead, CHAI and Penta to enhance HIV treatment for children

Gilead will transfer the technology for F/TAF’s dispersible dosage. Credit: Sundry Photography / Shutterstock.com. Gilead Sciences has entered into public-private collaborations with the Clinton Health Access

July 14, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.